Study Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Want to learn more about this trial?
Request More InfoInterventions
Dose Level 1, VNX-101GENETIC
Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
Dose Level 2, VNX-101GENETIC
Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
Dose Level 3, VNX-101GENETIC
Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
Dose Level 4, VNX-101GENETIC
Adeno-associated viral vector encoding the CD3/CD19 Bi-Specific T-Cell Engager (AAV.CD3/CD19), Single IV infusion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| City of Hope | Duarte | California | United States |
| Valkyrie Clinical Trials | Los Angeles | California | United States |
| Colorado Blood Cancer Institute | Denver | Colorado | United States |
| New York Medical College | Valhalla | New York | United States |
| University of North Carolina at Chapel Hill/ University of North Carolina Medical Center | Chapel Hill | North Carolina | United States |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | United States |
| Oregon Health & Science University | Portland | Oregon | United States |
| TriStar BMT | Nashville | Tennessee | United States |
| University of Texas MD Anderson Cancer Center | Houston | Texas | United States |